INSPRA 50 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

EPLERENONE

متاح من:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

ATC رمز:

C03DA04

الشكل الصيدلاني:

FILM COATED TABLETS

تركيب:

EPLERENONE 50 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

FAREVA AMBOISE, FRANCE

المجال العلاجي:

EPLERENONE

الخصائص العلاجية:

Inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < or = 40 % ) and clinical evidence of heart failure after recent myocardial infarction.Inspra is indicated in addition to standard optimal therapy, to reduce the risk of cardiovascular morbidity and mortality in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF < or = 30%).

تاريخ الترخيص:

2021-06-30

نشرة المعلومات

Inspra PIL CC 141221
2021-0074273
PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986
This medicine is dispensed with a doctor’s prescription only
INSPRA
® 25 MG
INSPRA
® 50 MG
FILM-COATED TABLETS
EACH TABLET CONTAINS:
EPLERENONE 25 MG, 50 MG
Inactive ingredients and allergens: See section 2 under ‘Important
information about some of
this medicine’s ingredients’ and section 6 ‘Further
information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This
leaflet contains concise
information about this medicine. If you have any further questions,
consult your doctor or
pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them,
even if it seems to you that their medical condition is similar to
yours.
1.
WHAT IS THIS MEDICINE INTENDED FOR?
•
In addition to standard therapy including beta-blockers, to reduce the
risk of
cardiovascular mortality and morbidity in stable patients with left
ventricular
dysfunction (LVEF < or = 40%) and clinical evidence of heart failure
after recent
myocardial infarction.
•
In addition to standard optimal therapy, to reduce the risk of
cardiovascular morbidity
and mortality in adult patients with NYHA class II chronic heart
failure and left
ventricular systolic dysfunction (LVEF < or = 30%).
THERAPEUTIC GROUP:
Selective aldosterone antagonists.
2.
BEFORE USING THIS MEDICINE
DO NOT USE THE MEDICINE IF:
Inspra PIL CC 141221
2021-0074273
•
you are sensitive (allergic) to the active ingredient or to any of the
additional
ingredients contained in the medicine (see section 6).
•
you suffer from high levels of potassium in the blood (hyperkalemia).
•
you are taking medicines of the potassium-sparing diuretics group.
•
you suffer from severe kidney disease.
•
you suffer from severe liver disease.
•
you are taking medicines that are used to treat fungal infection
(ketoconazole or
itraconazole).
•
you are taking antiviral medicines for treating HIV (ritonavir or
nelfinavir).
•

خصائص المنتج

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/